IDEXX LABORATORIES INC /DE — Director's Dealing 2018

Aug 23, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2018-08-21

Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-21	Common Stock	M	10000	$43.71	Acquired	1073469	Direct
2018-08-21	Common Stock	S	7000	$243.2026	Disposed	1066469	Direct
2018-08-22	Common Stock	M	20000	$43.71	Acquired	1086469	Direct
2018-08-22	Common Stock	S	3700	$245.1191	Disposed	1082769	Direct
2018-08-22	Common Stock	S	12300	$245.8940	Disposed	1070469	Direct
2018-08-23	Common Stock	M	10000	$43.71	Acquired	1080469	Direct
2018-08-23	Common Stock	S	7000	$247.3271	Disposed	1073469	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-21	Non-Qualified Stock Option (right-to-buy)	$43.71	M	10000	Disposed	2019-02-13	Common Stock (10000)	Direct
2018-08-22	Non-Qualified Stock Option (right-to-buy)	$43.71	M	20000	Disposed	2019-02-13	Common Stock (20000)	Direct
2018-08-23	Non-Qualified Stock Option (right-to-buy)	$43.71	M	10000	Disposed	2019-02-13	Common Stock (10000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	98000	Indirect

Footnotes

F1: Includes a total of 71 shares acquired under the registrant's Employee Stock Purchase Plan on March 30, 2018 and June 30, 2018.

F2: Represents the weighted average sales price of the shares sold ranging from a low of $243.1748 to a high of $243.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Represents the weighted average sales price of the shares sold ranging from a low of $244.63 to a high of $245.57 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: Represents the weighted average sales price of the shares sold ranging from a low of $245.69 to a high of $246.345 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: Represents the weighted average sales price of the shares sold ranging from a low of $247.32 to a high of $247.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: Grant of option to buy 58,857 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F7: Not applicable.